Document:

EX-10.10

 Exhibit 10.10 

Quotient Biodiagnostics Holdings Limited 

SHAREHOLDERS AGREEMENT 
 THIS
SHAREHOLDERS AGREEMENT (this “Agreement”) is made as of the 16 day of February, 2012, by and among Quotient Biodiagnostics Holdings Limited, a no par value liability company incorporated in Jersey, Channel Islands with registered
number 109886 (the “Corporation”), each holder of the Corporation’s A Preference Shares (“Series A Preferred”) and B Preference Shares (“Series B Preferred” and together with the Series A
Preferred, the “Preferred Stock”) listed on Schedule A hereto (the “Investors”), and the holders of the Corporation’s Ordinary Shares, A Deferred Shares, B Deferred Shares, C Deferred Shares, A Ordinary
Shares and B Ordinary Share (collectively, the “Common Stock”) listed on Schedule B hereto (the “Key Holders” and together with the Investors, the “Shareholders”). 

RECITALS 
 WHEREAS, the
Key Holders, the holders of Series A Preferred (the “Series A Holders”) and the Corporation desire to induce the Series B Holders (as defined below) to purchase shares of Series B Preferred pursuant to the Investment Agreement dated
as of the date hereof by and among the Corporation and certain of the Investors (the “Investment Agreement”) by entering into this Agreement in order to provide the Investors with the rights and privileges as set forth herein. 

NOW, THEREFORE, the Corporation, the Key Holders and the Investors, including the Series A Holders, each hereby agree as follows: 

SECTION 1. Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

“Affiliate” shall mean, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or
more general partners or managing members of: or shares the same management Corporation with, such Person. 
 “Agreement”
shall mean this Shareholders Agreement, as the same may be amended from time to time. 
 “Articles of Association” shall
mean the Corporation’s Articles of Association, as amended and/or restated from time to time. 
 “Board” shall mean
the Corporation’s Board of Directors. 
 “Closing Date” shall mean the date of closing of the Investment Agreement.

 “Code” means the U.S. Internal Revenue Code of 1986, as amended. 

“Common Stock” shall have the meaning set forth in the Preamble hereto. 

“Corporation” shall mean Quotient Biodiagnostics Holdings Limited, a limited liability company incorporated in Jersey,
Channel Islands, its successors and assigns. 
 “Derivative Securities” shall mean any securities or rights convertible
into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

“Exit Event” means (i) a Sale of the Corporation (other than pursuant to Section 3) where the Series B Holders will
receive an aggregate cash consideration at such closing less than US$2.1O per share; (ii) or any application for admission to trading or listing of the Corporation’s shares (or any class of shares) on NASDAQ or any recognized investment
exchange or other stock market approved by the Requisite Series B Holders where the price per share on listing or admission to trading is less than US$5.25 (both as adjusted for any share splits, share dividends, combinations, subdivisions,
recapitalizations or the like). For the avoidance of doubt, with respect to clause (i), the term “Exit Event” shall be deemed to include any Sale of the Corporation (other than pursuant to Section 3) in which the Series B Holders
receive less than two (2) times their aggregate gross investment in the Corporation as set forth in the Investment Agreement, and, with respect to clause (ii), the term “Exit Event” shall be deemed to include any application for
admission to trading or listing of the Corporation’s shares (or any class of shares) on NASDAQ or any recognized investment exchange or other stock market approved by the Requisite Series B Holders where the Series B Holders receive less than
five (5) times their aggregate gross investment in the Corporation as set forth in the Investment Agreement. 
 “Founder
Director” shall have the meaning ascribed to such term in the Articles. 
 “Galen” shall mean, collectively, Galen
Partners Y, L.P. and Galen Partners International V, L.P. and their respective Affiliates. 
 “Indemnified Tax Amount”
means the additional amount of U.S. federal, state and local tax due to (A) the inclusion of any amount in the income of an Investor under Sections 951(a)(I)(A) and (B) of the Code, (B) the recharacterization of a capital gain as a
dividend under Section 1248 of the Code (whether by operation by operation of Section 1248 or any other section of the Code), (C) the application of Section 367(b) of the Code, or (D) the treatment of any amount as an excess
distribution under Section 1291 of the Code due to the Corporation meeting the Asset Test due to its status as a “controlled foreign corporation” as such terms are defined in the Tax Memorandum; provided that, in each such
case, the additional tax is the result of the Corporation being a “controlled foreign corporation” due to the direct or indirect sale of Quotient Biodiagnostics Group Limited stock. The additional amount of U.S. federal, state and local
tax for a taxable year shall equal the amount of income included in the Investor’s gross income under (A), (B), (C) and (D) multiplied by the highest applicable U.S. federal, state and local statutory tax rates applicable to any Galen
partner or any member of the general partner of 

  
 2 

 
Galen in effect for such year. The tax so calculated with respect to any amount described in (B) shall be reduced by the amount of tax that such Galen partner or member of the general partner of
Galen would have paid had the income in question been characterized as capital gain. 
 “Investment Agreement” shall have
the meaning set forth in the Recitals hereto. 
 “Investor Director” shall have the meaning ascribed to such term in the
Articles. 
 “New Securities” shall mean, collectively, equity securities of the Corporation, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

“Permitted Share Issue” means an issue of shares pursuant to: 

 

	 	•	 	agreements entered into pursuant to Sections 5(b), (c) or (d); or 

  

	 	•	 	the warrants and options referred to in the Investment Agreement and as set forth in the Capitalization Table set out in Schedule C; 

“Person” shall mean any individual, corporation, partnership, trust, limited liability Corporation, association, organization
or other entity. 
 “QBDG” shall mean Quotient Biodiagnostics Group Limited, incorporated in Jersey, Channel Islands with
company number 103254. 
 “Requisite Series B Holders” shall mean the holders of at least a majority of the then
outstanding shares of Series B Preferred. 
 “Sale of the Corporation” shall mean a “Sale” as such term is
defined in the Articles of Association. 
 “Series A Preferred” shall have the meaning set forth in the Preamble hereto.

 “Series B holders” shall mean the holders of shares of Series B Preferred as set forth on Schedule A hereto. 

“Series B Preferred” shall have the meaning set forth in the Preamble hereto. 

“Shares” shall mean and include any securities of the Corporation the holders of which are entitled to vote for members of
the Board, including without limitation, all shares of Common Stock, Series A Preferred, and Series B Preferred, by whatever name called, now owned or subsequently acquired by a Shareholder, however acquired, whether through stock splits, stock
dividends, reclassifications, recapitalizations, similar events or otherwise. 

  
 3 

 “Tax Memorandum” means a memorandum on the U.S. federal income tax regimes
governing “controlled foreign corporations” and “passive foreign investment companies” as attached hereto as Schedule D. 
 SECTION 2.
Exercise of Voting Powers. Each Shareholder agrees to vote or cause to be voted all Shares owned or controlled by them as may be necessary, from time to time and at all times, in whatever manner as shall be necessary to (a) increase the
number of authorized shares of Common Stock from time to time to ensure that there will be sufficient shares of Common Stock available for conversion of all of the shares of Preferred Stock outstanding at any given time, and (b) implement the
Exit provisions contained in articles 6.2 and 6.3 of the Articles of Association 
 SECTION 3. Galen Unilateral Rights. 

(a) Accelerated Sale. 

(i) Commencement of Accelerated Sale. If, at any time following the date that is twenty four (24) months following the Closing
Date or if, at any time before such date the cash balance of the Corporation drops below $1,000,000 at any time for a continuous period of 60 days within the period extending from the Closing Date through the second anniversary of the Closing Date,
Galen may, in its sole discretion and without the need for additional approval by the Board or Shareholders, request (i) a Sale of the Corporation or (ii) that a third party be found to purchase the shares of Series B Preferred then held
by the Series B Holders (each, an “Accelerated Sale”). For the avoidance of doubt, Galen’s request for an Accelerated Sale shall not be subject to any conditions or contingencies. In order to initiate an Accelerated Sale, Galen
shall deliver written notice (an “Accelerated Sale Notice”) to either the Chief Executive Officer of the Corporation or the Board. The Accelerated Sale Notice shall specify whether Galen desires to proceed with a Sale of the
Corporation or to effect a sale of the Series B Holders’ shares of Series R Preferred to a third party. 
 (ii) Effecting an
Accelerated Sale. Following the receipt by the Corporation’s Chief Executive Officer or the Board, as applicable, of an Accelerated Sale Notice, the Corporation shall have a period of one (1) month to appoint an advisor to help
coordinate and effect the Accelerated Sale (the “Accelerated Sale Advisor”) and otherwise to begin the process of effecting an Accelerated Sale. The appointment of the Accelerated Sale Advisor shall be subject to the mutual
agreement of Galen and QHDG. Subject to Section 3(a)(iii), each of the Shareholders, including, without limitation, QBDG, hereby agree that such Shareholder will use all reasonable efforts to effect the Accelerated Sale in a timely manner,
including, without limitation, taking the following actions: (a) if such Accelerated Sale requires shareholder approval, with respect to all Shares that such Shareholder owns or over which such Shareholder otherwise exercises voting power, to
vote (in person, by proxy or by action by written consent, as applicable) all Shares in favor of, and adopt, such Accelerated Sale (together with any related amendment to the Articles required in order to implement such Accelerated Sale) and to vote
in opposition to any and all other proposals that could delay or impair the ability of the Corporation to consummate such Accelerated Sale; (b) to execute and deliver all related documentation and take such other action in support of the
Accelerated Sale as shall reasonably be requested by the 

  
 4 

 
Corporation, the Accelerated Sale Advisor or Galen in order to carry out the terms and conditions of this Section 3(a), including, without limitation, executing and delivering
instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens,
claims and encumbrances) and any similar or related documents; (c) not to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement or the Articles, any Shares of the Corporation owned by such Shareholder or
Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by the acquiror in connection with the Accelerated Sale; (d) to refrain from
exercising any dissenters’ rights or rights of appraisal under applicable law or preemption or similar rights contained in the Articles of Association at any time with respect to the Accelerated Sale; and (e) in the event that a
shareholder representative (the “Shareholder Representative”) is appointed in connection with the Accelerated Sale with respect to matters affecting the Shareholders under the applicable definitive transaction agreements following
consummation of such Accelerated Sale, (x) to consent to (i) the appointment of such Shareholder Representative, (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or
similar obligations, and (iii) the payment of such Shareholder’s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Shareholder Representative in connection with
such Shareholder Representative’s services and duties in connection with such Accelerated Sale and its related service as the representative of the Shareholders, and (y) not to assert any claim or commence any suit against the Shareholder
Representative or any other Shareholder with respect to any action or inaction taken or failed to be taken by the Shareholder Representative in connection with its service as the Shareholder Representative, absent fraud or willful misconduct. 

(iii) Notwithstanding any provision of this agreement or the Articles of Association, in the event Galen exercises its Accelerated Sale right
pursuant to this Section 3, the Corporation (in the event the Corporation receives an definitive offer from a third party with respect to such Accelerated Sale) or Galen (in the event Galen receives a definitive offer with respect to
such Accelerated Sale), as applicable, shall provide QBDG with notice of such offer and for a period of twenty eight (28) days following delivery of such notice QBDG shall have the right to consummate the Accelerated Sale with the Corporation
or the Series B Holders, as applicable, at the same price offered by such third party and on terms substantially similar to those offered by such third party. 

(iv) Liability in Accelerated Sale Documents. No Shareholder shall be required to comply with Section 3(a)(ii) or (iii) above
in connection with an Accelerated Sale unless: (1) any representations and warranties to be made by such Shareholder in connection with the Accelerated Sale are limited to representations and warranties related to authority, ownership and the
ability to convey title to such Shareholder’s shares or other securities in the Corporation, including but not limited to representations and warranties that (i) the Shareholder holds all right, title and interest in and to the shares or
securities such Shareholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Shareholder in connection with the transaction have been duly authorized, if applicable, (iii) the documents to be
entered into by the Shareholder have been duly executed by the Shareholder and delivered to 

  
 5 

 
the acquirer and are enforceable against the Shareholder in accordance with their respective terms and (iv) neither the execution and delivery of documents to be entered into in connection
with the transaction, nor the performance of the Shareholder’s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or judgment, order or decree of any court or governmental agency; and (2) the
liability for indemnification, if any, of such Shareholder in the Accelerated Sale and for the inaccuracy of any representations and warranties made by the Corporation or its Shareholders in connection with such Accelerated Sale, is several and not
joint with any other Person (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Corporation- as well as breach by any stockholder of any of identical
representations, warranties and covenants provided by all stockholders), and is pro rata in proportion to, and does not exceed, the amount of consideration paid to such Shareholder in connection with such Accelerated Sale. 

(v) Termination of Accelerated Sale. Notwithstanding the foregoing, Galen, in its sole discretion, may elect to cease the Accelerated
Sale process at any time by delivering written notice to the Corporation’s Chief Executive Officer or the Board, in which event the rights to effect an Accelerated Sale shall lapse and not be available for a second or subsequent sale. 

(b) Failure to Effect Accelerated Sale or Redeem Series B Preferred; Reconstitution of Board and Appointment of Executive Chairman. In
the event that (1) the Corporation has failed to effect an Accelerated Sale within twelve (12) months following the delivery by Galen of the Accelerated Sale Notice to the Corporation’s Chief Executive Officer or Board or (2) the
Corporation has failed to redeem or register the transfer of any shares of Series B Preferred in accordance with Article 12 of the Articles (each of the foregoing events, a “Unilateral Event”), then the size of the Board shall be
increased, and Galen shall have the right to appoint any and all directors to fill any vacancies created by such increase, until such time as the Galen representatives on the Board constitute a majority of the Board (the “Galen Board
Increase”). In addition, upon the occurrence of a Unilateral Event, Galen shall have the right to appoint an Executive Chairman of the Board (the “Executive Chairman Appointment”). Each Shareholder hereby agrees to vote, or
cause to be voted, all Shares owned by such Shareholder, or over which such Shareholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to effect the Galen Board Increase and/or the Executive Chairman
Appointment in accordance with the terms of this Section 3(b). 
 SECTION 4. 

(a) Matters Requiring Investor Approval. Subject to Galen’s rights and privileges set forth in Section 3 above, the
Corporation hereby covenants and agrees with each of the Series B Holders and QBDG that it shall not, without the prior written consent or affirmative vote of the Requisite Series B Holders and QBDG, take, or cause any of its subsidiaries to take,
any of the following actions (directly or indirectly by amendment, merger, consolidation or otherwise), and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect.

 (1) alter the Corporation’s Memorandum of Association or Articles or the rights attaching to any Shares (other than the conversion
of any shares in accordance with the Articles); 

  
 6 

 (2) issue any new Shares other than for a Permitted Share Issue; 

(3) grant any options or other equity interests other than for the purpose of a Permitted Share Issue; 

(4) declare, make or pay any dividend or other distribution; 

(5) pass any resolution to wind up, dissolve or liquidate the Corporation or any of the Corporation’s subsidiaries, including, without
limitation, close down any business operation or dispose of or dilute its interest in any of its subsidiaries; 
 (6) amalgamate or merge
with any other Corporation or business undertaking or enter into, vary or terminate any partnership, consortium or joint venture; 
 (7)
acquire any business or shares (other than in a group Corporation) or interest other than in a corporate or other entity; 
 (8) make,
increase or amend any borrowing (other than from banks in the ordinary course of business not in excess of £100,000 above the principal amount outstanding at Closing); 

(9) sell, transfer or dispose of or grant an option or other right over all or a substantial part of the Corporation’s undertakings and
assets, 
 (10) enter into any agreement to carry out or complete an Exit Event; 

(11) enter into or vary any transaction, arrangement or agreement with any director or shareholder of the Corporation or its subsidiaries or
any person connected with any such director or shareholder, other than an arms’ length employment agreement or agreement for services in the ordinary course of business; 

(12) establish or amend any material profit-sharing, share option, bonus, employee trust or other incentive schemes of any nature for
directors or employees other than for a Permitted Share Issue; 
 (13) increase the number of shares or equity securities reserved for
issuance under any option plan or other equity incentive scheme, including, without limitation, the Management Pool and the Independent Director Pool (each as defined below), in excess of the number of shares reserved in the Capitalization Table set
out in Schedule C; 
 (14) establish or amend any pension scheme; or grant any material pension rights to any director, employee, former
director or employee or any member of such person’s family; 
 (15) engage in any business other than the business of developing,
manufacturing and selling transfusion diagnostic products; or expend any monies or incur any liabilities other than in good faith for the purpose or in connection with the carrying on of the business or enter into any arrangement, contract or
transaction outside the normal course if its business or otherwise than on an arms length basis; 
 (16) enter into any commitment outside
the ordinary course of business which would involve the Corporation or its subsidiaries in the payment or receipt of consideration having an aggregate value in excess of £100,000 or enter into any commitment within the ordinary course of
business which would involve the Corporation or its subsidiaries in the payment of consideration having an aggregate value in excess of £100,000; 

  
 7 

 (17) grant, create or permit to be created any new encumbrance on any material asset or any
shares in the Corporation or its subsidiaries other than liens arising in the ordinary course of business; 
 (18) give any guarantee,
suretyship or indemnity to secure any liability of any other person (other than the Corporation or its subsidiaries) or assume any of the obligations of any other person; 

(19) enter into any operating lease for a duration exceeding five (5) years or involving aggregate premium and annual rental payments for
the Corporation or its subsidiaries in excess of £100,000; 
 (20) grant any rights (by license or otherwise) in or over any
intellectual property owned or used by the Corporation or its subsidiaries; 
 (21) change either its auditors or its accounting reference
date; 
 (22) make or permit to be made any material change in the accounting policies adopted by the Corporation or its subsidiaries; 

(23) make any loan or grant any credit or give any guarantee or indemnity, other than in the ordinary course of business; 

(24) agree to remunerate any officer of or consultant to the Corporation at an annual rate in excess of £100,000; 

(25) enter into or vary or (subject to any breach justifying termination) terminate any contract of employment providing for the payment of
remuneration in excess of £100,000 per annum; 
 (26) enter into any transaction reasonably likely to result in the Corporation
becoming a “controlled foreign corporation” for US tax purposes as further set out in the Tax Memorandum; 
 (27) subject to the
rights of Galen and QBDG to appoint and remove directors pursuant to Article 32 of the Articles of Association increase or decrease the size of the Board; or 

(28) effect or commit to any of the items listed in (1) through (27) above by a subsidiary of the Corporation. 

(b) Relationship with Articles of Association. For as long as this Agreement continues in force, in the event an action or matter
requiring the consent of the Requisite Series B Holders and QBDG pursuant to Section 4(a) has received Preference Consent (as defined in the Articles of Association) such action or matter shall be deemed to have been approved by the Requisite
Series B Holders and QBDG solely with respect to that specific instance in accordance with Section 4(a). 

  
 8 

 SECTION 5. Additional Covenants. 

(a) Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office (including the Founder
Director and at least one (1) Investor Director), the Board shall meet at least quarterly (either in person or via teleconference) in accordance with an agreed-upon schedule; provided that the Board shall meet in person at least one
(I) time each calendar quarter. The Corporation shall reimburse the non-employee directors for all reasonable out-of-pocket travel expenses incurred in connection with attending meetings of the Board (or any meetings of the board of directors
of any of the Corporation’s subsidiaries) or other Corporation business. When trans-Atlantic travel is required by Corporation business, reasonable travel expenses shall be deemed to include the cost of business class fare. The Corporation
shall cause to be established, as soon as practicable following the Closing, and will maintain, an audit and compensation committee, each of which shall include the Founder Director and at least one (1) Investor Director. Upon reasonable notice
to each member of the Board, each of Galen and QBDG shall have the right to convene a teleconference meeting of the Board. 
 (b)
Management Pool and Independent Director Pool. On the Closing, a total of 2,081,675 shares shall be reserved for the Corporation’s equity incentive option pool (the “Management Pool”) which shall include 250,182 Ordinary
Shares for issuance to future independent directors (the “Independent Director Pool”). Each Shareholder hereby agrees to vote, or cause to be voted, all Shares owned by such Shareholder, or over which such Shareholder has voting
control in whatever manner as shall be necessary to effect the increases to the Management Pool and the Independent Director Pool as set forth in this Section 5(b). As from Closing the share capital structure of the Corporation shall be
as set out in Schedule C. 
 (c) Equity Interests Granted to Directors. Unless otherwise approved by the Board, including at least
one (1) Investor Director, all directors of the Corporation who purchase, receive options to purchase, or receive awards of shares of the Corporation’s capital stock after the date hereof shall be required to execute restricted stock or
option agreements, as applicable, providing for the exercise of such options on an Exit Event (as defined in the Articles of Association) on terms consistent with standard QBDG option grants outstanding as of the date hereof. In addition, unless
otherwise approved by the Board, including at least one (1) Investor Director, the Corporation shall have the right to repurchase any shares issued from the Independent Director Pool at the then fair market value of such shares as determined in
good faith by the Board and otherwise on terms set out in the Articles of Association. 

  
 9 

 (d) Equity Interests Granted to Employees and Consultants Prior to Closing. All options
and deferred shares granted to employees and consultants of QBDG, Alba (as defined in the Investment Agreement), QBD Inc. (as defined in the Investment Agreement), the Corporation or its subsidiaries which are in issue and outstanding immediately
prior to the Closing, shall continue in accordance with the terms applicable to such options and deferred shares as in effect immediately prior to Closing subject only to those amendments arising pursuant to the new option agreements with the
Corporation to be entered into on or promptly following the date of this Agreement or on such later date as the Board may determine; provided that aforementioned options and deferred shares are set forth in the Capitalization Table set forth
out on Schedule C. 
 (e) Insurance. The Corporation shall use its commercially reasonable efforts to obtain, within ninety
(90) days of the date hereof, from financially sound and reputable insurers Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board, and will use commercially reasonable efforts to cause
such insurance policies to be maintained until such time as the Board determines that such insurance should be discontinued. 
 (f)
Successor Indemnification. If the Corporation or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the
extent necessary, proper provision shall be made so that the successors and assignees of the Corporation assume the obligations of the Corporation with respect to indemnification of members of the Board as in effect immediately before such
transaction, whether such obligations are contained in the Articles, or elsewhere, as the case may be. 
 (g) Registration Rights. In
the event the Corporation grants any future rights or privileges to any existing or future holders of shares of capital stock of the Corporation that are not also applicable to the Series B Holders, the Corporation shall grant to the Series B
Holders such additional rights or privileges. Without limiting the foregoing, if, following the Closing, the Corporation sells or issues any securities, whether or not currently authorized (including securities convertible into or exchangeable or
exercisable for any shares of the Corporation’s capital stock), that entitles any holder thereof to registration rights, including, without limitation, demand and piggyback registration rights, with respect to such securities (or any shares of
capital stock issuable upon conversion or exercise of such securities) (the “Registration Rights”), then the Corporation shall grant the same Registration Rights to the Series B Holders (or Ordinary Shares issuable upon conversion
of the shares of Series B Preferred). 
 (h) Passive Foreign Investment Company. The Corporation shall use commercially reasonable
efforts to avoid being a “passive foreign investment company” or “PFIC” as such term is described in the Tax Memorandum. The Corporation shall make due inquiry with its U.S. tax advisors at least annually regarding the
Corporation’s status as a PFIC and if the Corporation becomes a PFIC, or if there is a likelihood of the Corporation being a PFIC for any taxable year, the Corporation shall promptly notify Investors of such status or risk, as the case may be.
The Corporation shall, as soon as reasonably practicable following the end of each taxable year of the Corporation (but in no event later than sixty (60) days following the end of each taxable year) provide Investors with an accurate and
complete PFIC Annual Information Statement in the form set out in the Tax Memorandum. 

  
 10 

 (i) Controlled Foreign Corporation. The Corporation shall use commercially reasonable
efforts to avoid being a “controlled foreign corporation” or “CFC” as such term is described in the Tax Memorandum. The Corporation shall make due inquiry with its U.S. tax advisors at least annually regarding the
Corporation’s status as a CFC and if the Corporation becomes a CFC, or if there is a likelihood of the Corporation being a CFC for any taxable year, the Corporation shall promptly notify Investors of such status or risk, as the case may be. In
the event the Corporation is a CFC, it shall provide the Investors with any information that may reasonable request in order to allow the Investors to properly file their U.S. federal income tax returns. 

(j) Indemnified Tax Amount. If the Corporation engages in any transaction that causes any Indemnified Tax Amount to be payable by any
Investor, the Corporation shall indemnify such Investor with an amount equal to the Indemnified Tax Amount provided that: 
  

	 	a.	The Corporation shall be kept fully and timely informed of all matters relating to the tax reporting of any income or gain that gives rise to an Indemnified Tax Amount and shall in good faith consider adopting any tax
reporting position proposed by the Corporation that reduces any Indemnified Tax Amount; provided, however, that the Investor shall not adopt any such position unless, in the opinion of the Investor’s tax counsel and its tax return
preparer, the Investor would be more likely than not to prevail if such position were challenged by the Internal Revenue Service and the Investor fully exhausted all administrative and judicial remedies available to it in order to sustain such
filing position; 

  

	 	b.	Payment of the Indemnified Tax Amount shall be made no later than five (5) business days before the date of which the Investor (or its partners) is obliged to make the payment of tax to which the Indemnified Tax
Amount relates; and 

  

	 	c.	The Investor shall not make any admission of liability, settlement or compromise of the Tax Claim, or agree to any matter in the conduct of such Tax Claim which may affect the amount of the Indemnified Tax Amount
without the prior approval of the Corporation, such approval not to be unreasonably withheld or delayed. 

 SECTION 6. Third Party Financing.

 (a) In the event of an offer to finance (a “Financing Offer”) the Corporation or any successor or assignee of the
Corporation established or operating to hold all or substantially all of the assets of the Corporation (the “Corporation Successor”) that (i) is made on bona fide arms’ length terms approved the Board, (ii) includes
any offer of securities in the Corporation or Corporation Successor, as applicable, (iii) is in compliance with the provisions of Article 8 of the 

  
 11 

 
Articles of Association (Further Issue of Shares) (which shall be deemed to apply to any subsidiary of the Corporation or Successor Corporation) (the “Preemption Rights”), and
(iv) either Galen or QBDG has declined to participate (a “Non-Participating Investor”) in accordance with the Preemption Rights, then the Non-Participating Investor shall not exercise any of such Non-Participating
Investor’s rights under Section 4(a) or as set forth in the Preemption Rights in respect of such Financing Offer. 
 (b) If,
following closing of the Financing Offer, the Non-Participating Investor holds less than 25% of the total voting rights of the Corporation or the Corporation Successor, as applicable, such Non-Participating Investor’s rights under this
Agreement and such Non- Participating Investor’s rights as Investor or Founder, as applicable, under the Articles of Association (including with respect to voting and Minimum Return (as defined in the Articles of Association)) shall terminate
and such Non-Participating Investor shall exercise all voting rights and other powers of control and execute all documents and carry out all acts required by Galen or QBDG, as applicable, to carry out and complete such Financing Offer, provided that
the terms of Section 3(a)(iv) shall apply with respect to any such documents entered into by a Non- Participating Investor mutatis mutandis. 
 SECTION
6. Remedies 
 (a) Grant of Proxy: No Conflicting Agreements. Upon the failure of any Shareholder to vote its Shares in
accordance with the terms of this Agreement, such Shareholder hereby grants to a shareholder designated by the Board a proxy coupled with an interest in all Shares owned by such Shareholder, which proxy shall be irrevocable until this Agreement
terminates pursuant to its terms or this Section 6(a) is amended to remove such grant of proxy in accordance with Section 7(e) hereof, to vote all such Shares in the manner as provided herein. Each Shareholder hereby revokes
any and all previous proxies or powers of attorney with respect to such Shareholder’s Shares and shall not hereafter, until this Agreement terminates pursuant to its terms or this Section 6(a) is amended to remove this provision in
accordance with Section 7(e) hereof: grant, or purport to grant, any other proxy with respect to such Shares, deposit any of such Shares into a voting trust or enter into any agreement (other than this Agreement), arrangement or
understanding with any person, directly or indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of such Shares, in each case, with respect to any of the matters set forth in this Agreement. 

(b) Specific Enforcement. It is agreed and understood that monetary damages would not adequately compensate an injured party for the
breach of this Agreement by any other party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order.
Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach. 
 (c)
Remedies Cumulative. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 12 

 (d) Exercise of Remedies. Where any right or remedy hereunder accrues to the holders of any class
of share in the Corporation, such rights shall be exercisable only with the consent of holders of the majority of the shares in such class from time to time. 

(e) Conflict with Articles. If there shall be any conflict between the terms of this Agreement and the Articles of Association, as
between the Shareholders the terms of this Agreement shall prevail. 
 SECTION 7. Miscellaneous. 

(a) Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively
given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail (including PDF) or facsimile if sent during normal business hours of the recipient; if not, then on the next business day,
(c) five (5) days after having been sent by first class mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with
written verification of receipt. All notices and other communications shall be sent to the Corporation at its principal office, Attention: Chairman, and to the other parties at the addresses set forth on Schedule A or Schedule B, as
applicable (or at such other addresses as shall be specified by notice given in accordance with this Section 7(a)). 
 (b)
Assignment of Rights. 
 (i) The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement 
 (ii) Any successor or
permitted assignee of any Key Holder shall deliver to the Corporation and the Investors, as a condition to any transfer or assignment, an instrument of adherence hereto pursuant to which such successor or permitted assignee shall confirm their
agreement to be subject to and bound by all of the provisions set forth in this Agreement that were applicable to the predecessor or assignor of such successor or permitted assignee. 

(iii) The rights of the Investors hereunder are not assignable without the Corporation’s written consent (which shall not be
unreasonably withheld, delayed or conditioned), except (i) by an Investor to any Affiliate, partner, retired partner, member or retired member of such Investor, or (ii) to an assignee or transferee who acquires all of the Shares then held
by a particular Investor, it being acknowledged and agreed that any such assignment, including an assignment contemplated by the preceding clauses (i) or (ii) shall be subject to and conditioned upon any such assignee’s delivery to
the Corporation and the other investors of an instrument of adherence hereto pursuant to which such assignee shall confirm their agreement to be subject to and bound by all of the provisions set forth in this Agreement that were applicable to the
assignor of such assignee. 
 (iv) Except in connection with an assignment by the Corporation by operation of law to the acquirer of the
Corporation, the rights and obligations of the Corporation hereunder may not be assigned under any circumstances. 

  
 13 

 (c) Future Issuances to Key Holders. This Agreement and the rights and obligations of the
parties hereunder shall inure to the benefit of, and be binding upon, the Corporation’s Key Holders with respect to future issuances to Key Holders by the Corporation of additional Shares. 

(d) Term. This Agreement shall be effective as of the date hereof and shall continue in effect until and shall terminate upon the
earliest to occur of (a) the consummation of an Exit Event (as defined in the Articles of Association), or (b) termination of this Agreement in accordance with Section 6 or 7(e) below. 

(e) Consent Required to Amend, Terminate and Waive. This Agreement may be amended or terminated and the observance of any term hereof
may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (a) the Corporation, (b) the Investors holding a majority of the outstanding shares of Series A
Preferred then held by all of the Investors and (c) the Investors holding a majority of the outstanding shares of Series B Preferred then held by all of the Investors. Notwithstanding the foregoing, Sections 3, 4, 5 and
6 shall be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Requisite Series B Holders and QBDG. Any termination, amendment or waiver so effected
shall be binding upon all the parties hereto and all parties’ respective successors and permitted assigns, whether or not any such party, successor or assign entered into or approved such amendment or waiver. Notwithstanding the foregoing, any
provision hereof may be waived by the waiving party on such party’s behalf, without the written consent of any other party. Any waiver of any specific right or benefit hereunder shall not prejudice the enforcement or exercise of any similar
right or remedy in the future. 
 (f) Governing Law. This Agreement shall be governed by and construed under the laws of Jersey in
all respects as such laws are applied to agreements among Jersey residents entered into and performed entirely within Jersey, without giving effect to conflict of law principles thereof. 

(g) Severability. In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby. 
 (h) Title and
Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and arc not to be considered in construing this Agreement. 

(i) Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to any other relief to which such party may be entitled. 

  
 14 

 (j) Aggregation of Stock. All securities held or acquired by affiliated entities
(including affiliated venture capital funds) or persons shall be aggregated together for purposes of determining the availability of any rights under this Agreement. 

(k) Additional Key Holders. In the event that after the date of this Agreement, the Corporation issues shares of capital stock to any
person or entity, which shares constitute one percent (1%) or more of the Corporation’s then outstanding capital stock (including all shares of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or
convertible securities, as if exercised or converted), the Corporation shall, as a condition to such issuance, cause such person or entity to execute an instrument of adherence hereto, as a Key Holder, in a form approved by the Board, and such
person or entity shall thereby be bound by, and subject to, all the terms and provisions of this Agreement applicable to a Key Holder. 

(l) Entire Agreement. This Agreement (including any Exhibits and Schedules hereto), the Articles, the Investment Agreement and the
other Transaction Agreements (as defined in the Investment Agreement) constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the
subject matter hereof existing between the parties is expressly canceled. 
 (n) Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and
any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 (o)
Stock Split. All references to numbers of shares in this Agreement shall be appropriately adjusted to reflect any stock dividend, split, combination or other recapitalization affecting the Shares occurring after the date of this Agreement.

  
 15 

 IN WITNESS WHEREOF, the parties hereto have executed this Shareholders Agreement as of the date
first above written. 
  

			
	COMPANY:
	
	QUOTIENT BIODIAGNOSTICS HOLDINGS LIMITED
		
	By:	 	 /s/ Paul Cowan

	Name:	 	PAUL COWAN
	Title:	 	DIRECTOR
	
	INVESTORS:
	
	QUOTIENT BIODIAGNOSTICS GROUP LIMITED
		
	By:	 	 /s/ Paul Cowan

	Name:	 	PAUL COWAN
	Title:	 	DIRECTOR

  

[SIGNATURE PAGE TO SHAREHOLDERS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this Shareholders Agreement as of the date
first above written. 
  

			
	INVESTORS:
	
	GALEN PARTNERS V, L.P.
		
	By:	 	Galen Partners V, L.L.C., its General Partner
		
	By:	 	/s/ Zubeen Shroff
	Name:	 	Zubeen Shroff
	Title:	 	Managing Director
	
	GALEN PARTNERS INTERNATIONAL V, L.P.
		
	By:	 	Galen Partners V, L.L.C., its General Partner
		
	By:	 	 /s/ Zubeen Shroff

	Name:	 	Zubeen Shroff
	Title:	 	Managing Director
	
	THOMAS BOLOGNA
	
	 

  

[SIGNATURE PAGE TO SHAREHOLDERS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this Shareholders Agreement as of the date
first above written. 
  

			
	INVESTORS:
	
	GALEN PARTNERS V, L.P.
		
	By:	 	Galen Partners V, L.L.C., its General Partner
		
	By:	 	 
	Name:	 	Zubeen Shroff
	Title:	 	Managing Director
	
	GALEN PARTNERS INTERNATIONAL V, L.P.
		
	By:	 	Galen Partners V, L.L.C., its General Partner
		
	By:	 	 
	Name:	 	Zubeen Shroff
	Title:	 	Managing Director
	
	THOMAS BOLOGNA
		
		 	/s/ Thomas Bologna

  

[SIGNATURE PAGE TO SHAREHOLDERS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this Shareholders Agreement as of the date
first above written. 
  

			
	KEY HOLDERS:	  	
		
	 /s/ Paul Cowan
	  	BY HIS DULY AUTHORISED ATTORNEY
	  
	  	
	 Paul Cowan 
	  	
		
	 /s/ Paul Cowan
	  	BY HIS DULY AUTHORISED ATTORNEY
	  
	  	
	 Paul Cowan 
	  	
		
	 /s/ Paul Cowan
	  	BY HIS DULY AUTHORISED ATTORNEY
	  
	  	
	 Paul Cowan 
	  	

  

[SIGNATURE PAGE TO SHAREHOLDERS AGREEMENT] 

 Schedule A 

Investors 
 Series B Holders 

Galen Partners V, L.P. 
 680 Washington Boulevard 

11th Floor 
 Stamford, CT 06901 

Attn: David Azad 
 Galen Partners International V, L.P. 

680 Washington Boulevard 
 11th Floor 

Stamford, CT 06901 
 Attn: David Azad 

Thomas Bologna 
 148 Hodge Road 

Princeton, NJ 08540 
 Series A Holders 

Quotient BioDiagnostics Group Limited 
 PO Box 1075 

Elizabeth House 
 9 Castle Street 

St Helier 
 Jersey 

JE4 2QP 

 Schedule B 

Key Holders 
 Jeremy Stackawitz 

1551 Wexford Court 
 Newton 

PA 18940 
 USA 

Michael Hannan 
 703 Damascus Church Road 

Chapel Hill 
 NC 27516 

USA 
 William Brady 

606 Meadowmount Lane 
 Chapel Hill 

NC 27517 
 USA 

 Schedule C 

Capitalization Table 
  

																											
	 Shareholder Name
	  	 Class of Share
	  	Shares to be
Issued on
Closing	 	  	Warrants	  	Shares in
issue post-
Warrant
exercise	 	  	Options	  	Shares in
issue post-
option
exercise	 	  	% of fully-
diluted
Equity	 	 	% of
Votes	 
									
	 Jeremy Stackawitz
	  	A Deferred Shares	  	 	39,539	  	  		  	 	39,539	  	  		  	 	39,539	  	  	 	0.13	% 	 	 	0.00	% 
		  	A Ordinary Shares	  	 	138,386	  	  		  	 	138,386	  	  		  	 	138,386	  	  	 	0.45	% 	 	 	0.00	% 
		  	B Deferred Shares	  	 	118,617	  	  		  	 	118,617	  	  		  	 	118,617	  	  	 	0.38	% 	 	 	0.00	% 
		  	C Deferred Shares	  	 	300,000	  	  		  	 	300,000	  	  		  	 	300,000	  	  	 	0.97	% 	 	 	0.00	% 
									
	 Michael Hannan
	  	A Deferred Shares	  	 	9,885	  	  		  	 	9,885	  	  		  	 	9,885	  	  	 	0.03	% 	 	 	0.00	% 
		  	A Ordinary Shares	  	 	19,769	  	  		  	 	19,769	  	  		  	 	19,769	  	  	 	0.06	% 	 	 	0.00	% 
		  	C Deferred Shares	  	 	112,855	  	  		  	 	112,855	  	  		  	 	112,855	  	  	 	0.37	% 	 	 	0.00	% 

																															
	 William Brady
	  	A Deferred Shares	  	 	9,885	  	  				 	 	9,885	  	  				  	 	9,885	  	  	 	0.03	% 	 	 	0.00	% 
		  	A Ordinary Shares	  	 	19,769	  	  				 	 	19,769	  	  				  	 	19,769	  	  	 	0.06	% 	 	 	0.00	% 
		  	 C Deferred Shares
	  	 	112,855	  	  				 	 	112,855	  	  				  	 	112,855	  	  	 	0.37	% 	 	 	0.00	% 
									
	 QBDG
	  	A Preference	  	 	12,469,954	  	  	 
  
	950,060
 (Series A
	  
 ) 
	 	 	13,420,014	  	  				  	 	13,420,014	  	  	 	43.54	% 	 	 	48.17	% 
									
	 Galen Partners
	  	B Preference	  	 	10,450,653	  	  	 
  
	3,762,316
 (Series B
	  
 ) 
	 	 	14,212,969	  	  				  	 	14,212,969	  	  	 	46.11	% 	 	 	51.01	% 
									
	 Tom Bologna
	  	B Preference	  	 	190,011	  	  	 
  
	37,921
 (Series B
	  
 ) 
	 	 	227,932	  	  				  	 	227,932	  	  	 	0.74	% 	 	 	0.82	% 
									
	 Total Shares
	  		  	 	23,992,178	  	  				 	 	28,742,475	  	  				  	 	28,742,475	  	  	 	93.25	% 	 	 	0.00	% 
									
	 Shares Reserved for Issue Against Current QBDG Share Options (to be replaced by QBDH Share Options
	  	Ordinary Shares	  				  				 				  	 	505,009	  	  	 	505,009	  	  	 	1.64	% 	 	 	0.00	% 

																															
	 Shares Reserved for Issue Against Options to be granted to Directors
	  		  	 	            	  	  	 	            	  	  	 	            	  	  				  				  				 			
	 John Wilkerson
	  	Ordinary Shares	  				  				  				  	 	62,546	  	  	 	62,546	  	  	 	0.20	% 	 	 	0.00	% 
	 David Azad
	  	Ordinary Shares	  				  				  				  	 	62,546	  	  	 	62,546	  	  	 	0.20	% 	 	 	0.00	% 
	 Tom Bologna
	  	Ordinary Shares	  				  				  				  	 	125,091	  	  	 	125,091	  	  	 	0.41	% 	 	 	0.00	% 
	 Fred Hallsworth
	  	Ordinary Shares	  				  				  				  	 	42,546	  	  	 	42,546	  	  	 	0.14	% 	 	 	0.00	% 
	 Paul Cowan
	  	Ordinary Shares	  				  				  				  	 	62,546	  	  	 	62,546	  	  	 	0.20	% 	 	 	0.00	% 
	 Independent Board Member
	  	Ordinary Shares	  				  				  				  	 	125,091	  	  	 	125,091	  	  	 	0.41	% 	 	 	0.00	% 
	 Shares Reserved for Future Share Option/Management Equity Issues
	  	Various	  				  				  				  	 	1,096,300	  	  	 	1,096,300	  	  	 	3.56	% 	 	 	0.00	% 
		  		  				  				  				  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	  
	  
	 
	 Totals
	  		  				  				  				  	 	2,081,675	  	  	 	30,824,150	  	  	 	100.00	% 	 	 	100.00	% 
		  		  				  				  				  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	  
	  
	 

 Schedule D 

Tax Memorandum 
 MEMORANDUM 

 
  
  

			
	TO:	  	The Board of Directors of Quotient Biodiagnostics Holdings Limited
		
	FROM:	  	Mark Hrenya
		
	DATE:	  	January 30, 2012
		
	RE:	  	Tax Memorandum

  
  

IRS Circular 230 disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax advice contained in
this analysis is not intended or written by us to be used, and cannot be used, for the purpose of avoiding tax penalties under the Internal Revenue Code of 1986, as amended. 

BACKGROUND 
 This
memorandum is the “Tax Memorandum” as defined in the Quotient Biodiagnostics Holdings Limited Shareholders Agreement dated January     , 2012. It discusses the “controlled foreign corporation”
(“CFC”) and “passive foreign investment company” (“PFIC”) anti-deferral regimes in the United States Internal Revenue Code of 1986, as amended, and is being issued in conjunction with the acquisition of Quotient
Biodiagnostics Holdings Limited (“QBDH”) B Preference Shares by Galen Partners V, L.P. and Galen Partners International V, L.P. 
 The memorandum
provides a very general and very high level overview of these two very complex tax regimes. It defines the terms “controlled foreign corporation” and “passive foreign investment company” in order to assist the Board of Directors
of Quotient Biodiagnostics Holdings Limited (“QBDH”) with identify transactions1 that could result in QBDH being a CFC or PFIC. It also provides steps QBDH may take to mitigate the
adverse tax consequences on its U.S. shareholders due to its status as a CFC or PFIC. This discussion does not address all possible situations in which QBDH could become a CFC or PFIC or all steps it might take to mitigate the related tax
consequences on its U.S. shareholders. Hence, it is not intended to be used, and it should not be used, as a substitue for professional tax advice on prospective transactions. 

CONTROLLED FOREIGN CORPORATION REGIME 

Income Inclusion Rules. A “U.S. Shareholder” of a CFC must include in gross income for the purpose of calculating its U.S. federal
income tax, its pro rata share of the undistributed CFC’s “Subpart F income” and any increase in the CFC’s earnings invested in “U.S. property”. Gain realized by a U.S. Shareholder on the sale of stock of a CFC is
characterized as a dividend to the extent of the U.S. Shareholder’s pro rata share of the CFC’s accumulated earnings and profits and taxed at ordinary income tax rates. Thus, if QBDH becomes a CFC Galen Partners V, L.P. (and its U.S.
partners) will be taxed on certain undistributed income earned by QBDH and its subsidiaries. In addition, gain recognized from the sale of QBDH stock would be classified as ordinary income (currently taxed at rates up to 35%) to the extent of
Galen’s allocable share of QBDH accumulated earnings, as opposed to being classified as long-term capital gain (currently taxed at rates up to 15%). As a consequence, QBDH and its shareholders should avoid any transactions that result in QBDH
and its subsidiaries being classified as CFCs. 
  

	1 	The term “transactions” for this purpose includes transactions and contractual arrangements among QBDH group members. 

 In the event they are classified as CFCs, steps should be taken to avoid whenever possible, transactions that
will result in an income inclusion. 
 “United States Shareholder” A “U.S. Shareholder” is any U.S. person (including a
partnership organized in the United States) that owns or is treated as owning 10% or more of the total voting power of a foreign corporation’s stock. The regulations generally measure the voting power of each class according to the percentage
of the board of directors that the class can elect or replace and then divide the voting power of the class among the persons that own shares of that class. A U.S. person is treated as meeting the 10% threshold if that person owns 20% or more of the
number of shares of a class of stock that has the power to elect a majority of the board of directors. The following rules are applied for the purpose of determining whether these thresholds are satisfied. 

 

	 	•	 	Foreign Entity Attribution. Stock owned by or for a foreign corporation, foreign partnership, foreign trust, or foreign estate is treated as owned proportionately by the entity’s shareholders, partners, or
beneficiaries. The attribution does not stop until the stock is attributed to a foreign individual or a U.S. person. 

  

	 	•	 	Constructive Ownership. Stock actually owned by an individual’s spouse, children, grandchildren, and parents is treated as owned by the individual except when the rule would treat a U.S. citizen or resident
alien individual as owning stock owned by a nonresident alien individual. The constructive ownership rules also attribute stock between domestic entities and their owners and treat options on stock of a corporation as having been exercised, but only
to the extent that such treatment would result in a U.S. person being a U.S. Shareholder or the foreign corporation a CFC. 

 Controlled
Foreign Corporation. A foreign corporation is a CFC if more than 50% of either the total combined voting power of its stock entitled to vote or the total value of its stock is owned (or treated as owned) by “U.S.
Shareholders” on any day during the foreign corporation’s taxable year. 
  

	 	•	 	Voting-power test. If U.S. Shareholders own more than 50% of the voting power of the stock of a foreign corporation, it is a CFC, regardless of the value of such stock. A foreign corporation is a CFC if U.S.
Shareholders can elect, appoint, or replace a majority of the board of directors. The same result occurs if the U.S. Shareholders can elect half of the board and one or more of those directors has the power to cast a vote to break any deadlock. If a
foreign corporation has a class of stock with the power to elect over half of the corporation’s directors, a U.S. shareholder may have over half of the total voting power simply by owning over half of that class of stock. 

 

	 	•	 	Value test. A corporation may also be a CFC if U.S. Shareholders own over half its stock by value, even if they do not satisfy the voting power test. As a result, the word “controlled” is a misnomer in
some cases. The value test can be applied only if the relative values of FC’s preferred and common shares are known. If the preferred stock held by C is worth over 50 percent of the total value of all the common and preferred
stock, FC is a controlled foreign corporation. Because the relative values of preferred and common stock may shift over time, a foreign corporation may become a CFC without a change in stock ownership. 

 

	 	•	 	Example. Assume Galen Partners V, L.P. owns stock representing 40% of the voting power and 40% of the value of the stock of QBDH. A Quotient Bioscience shareholder sells 50% of the shares of Quotient
Bioscience’s only class of stock to a U.S. citizen. The U.S. citizen will be deemed to own 10.6% of the voting power of QBDH stock and therefore the U.S. citizen will be a U.S. Shareholder. QBDH will also be a CFC because the U.S. citizen and
the Galen fund will own more than 50% of the voting power of the stock of QBDH. 

 Subpart F Income. If QBDH is a CFC, each U.S. Shareholder will be required to include in gross
income, its’ pro rata share of QBDH’s Subpart F income which includes “Foreign Base Company Income” or “FBCI”. Under a de minimis exception, a CFC’s FBCI is zero if it is less than both (i) 5% of the
CFC’s gross income, and (ii) U.S. $1,000,000. Income is not FBCI if it is taxed at an effective foreign tax rate that exceeds 31.5%. In addition, a U.S. Shareholder is not required to pick up its pro rata share of FBCI in any year in which
a CFC has a deficit in its earnings and profits. 
 QBDH’s FBCI is likely to fall within two (of several) FBCI categories: (i) foreign personal
holding company income (“FPHCI”) and (ii) foreign base company sales income (“FBCSI”). 
  

	 	•	 	Foreign Personal Holding Company Income. FPHCI generally consists of passive income comprised of the following: 

dividends, interest, royalties, rents, and annuities; 

net gains from certain property transactions; 

net gains from certain commodities transactions; 

certain foreign currency gains; 

income equivalent to interest; 

income from notional principal contracts; 

certain payments in lieu of dividends; and 

amounts received under certain personal service contracts. 
  

	 	•	 	Exceptions. There are several exceptions that apply to income earned from the active conduct of a trade or business provided certain conditions are satisfied. These exceptions generally do not apply to income
received by a CFC from a group company organized in another country. 

  

	 	•	 	Example. Assume that QBDG through its subsidiary Alba develops certain intellectual property for which it obtains a patent. Alba makes an election to be treated as a disregarded entity for U.S. federal tax
purposes and therefore its development activities are treated as development activities of QBDG. QBDG grants two licenses: one to Company X located in country Y and another to its U.S. subsidiary Quotient. Royalties received from Company X would not
be FPHCI but royalties received from Quotient would be FPHCI. 

  

	 	•	 	Foreign Base Company Sales Income. FBCSI may come in a variety of forms, including profits, commissions, fees, or other income, and may involve a CFC that either buys and sells for its own account or acts as the
agent for a related person. FBCSI always involves the purchase or sale of personal property. A CFC may have FBCSI as a result of participating in any of four basic types of transactions. The property involved in each transaction must be made
and used outside the country in which the CFC is organized. 

  

	 	•	 	Categories of FBCSI. The four basic types of transactions that give rise to FBCSI include transactions in which – 

  

	 	•	 	A CFC buys personal properly from a related person and sells it to anyone. FBCSI results, however, only if (1) the property is manufactured outside the country under the laws of which the CFC is organized,
and (2) the property is sold for use, consumption, or disposition outside that foreign country. 

  

	 	•	 	A CFC buys personal property from anyone and sells it to related person. FBCSI results, however, only if (1) the property is manufactured outside the country under the laws of which the CFC is organized, and
(2) the property is sold for use, consumption, or disposition outside that country. 

	 	•	 	A CFC buys personal property from anyone on behalf of related person (i.e., it functions as a purchasing agent), FBCSI results, however, only if (I) the property is manufactured outside the country under the
laws of which the CFC is organized, and (2) the property is sold for use, consumption, or disposition outside that country. 

  

	 	•	 	A CFC sells personal property on behalf of related person (i.e., it functions as a sales agent). FBCSI results, however, only if (1) the property is manufactured outside the country under the laws of which
the CFC is organized and (2) the property is sold for use, consumption, or disposition outside that country. 

  

	 	•	 	Exception. FBCSI does not result if the CFC manufactures the property. Thus, if a CFC buys property, transforms it in some way, and then sells it the resulting income will not be FBCSI. The key issue is whether the CFC
should be treated as buying and selling the same property or as selling property it manufactured. A CFC may be treated as manufacturing property manufactured by a third party for it pursuant to a contract if the CFC substantially participates in the
manufacturing process. 

  

	 	•	 	Example. Q-Screen purchases product from an unrelated manufacturer located in India which Q-Screen does not manufacture under U.S. tax principles. Q-Screen sells product to Alba which in turn sells product to a
company located in the United Kingdom. The income earned by Q-Screen is FBCSI under the second category of FBCSI described above. 

Increase in Earnings Invested in U.S. Property. A U.S. Shareholder of a CFC generally must include in gross income its pro rata shares of the
increase in the earnings invested by the CFC in “U.S. property” for the taxable year. “U.S. property” is defined to include four basic types of property: (1) tangible property located in the United States; (2) stock of
a domestic corporation; (3) obligations of U.S. persons; and (4) certain items such as patents and copyrights used in the United States. 
 Very
generally, the amount of the income included in the U.S. Shareholder’s gross income under this provision is equal to the lesser of the adjusted basis of the U.S. property and the earnings and profits of the CFC. A U.S. Shareholder generally
disregards any U.S. property that was acquired by the CFC before the first day on which it was treated as a CFC. The amount disregarded may not exceed the earnings accumulated in periods before the first day the foreign corporation became a CFC.
Thus, QBDH’s investment in Quotient Biodiagnostics, Inc. could result in Galen Partners V, L.P. being required to include an amount in gross income for U.S. federal income tax purposes, if QBDH becomes a CFC and additional QBDH earnings are
invested in the subsidiary thereafter. 
 PASSIVE FOREIGN INVESTMENT COMPANY
REGIME 
 Passive Foreign Investment Company. A foreign corporation is a PFIC if at least (i) 75% of its gross
income for any taxable year consists of passive income (the” Income Test”), or (ii) 50% of the average value of its assets for the year produce or are held for the production of passive income (the “Asset Test”). Passive
income is comprised of FPHCI as defined under the CFC rules. Asset values are generally determined using fair market values at the end of each fiscal quarter, but adjusted tax basis must be used if the foreign corporation is a CFC, (increasing the
risk that the corporation will be a PFIC because the foreign corporation has no adjusted tax basis in its intellectual property – a non-passive asset). While cash and temporary investments may in fact represent a company’s working capital,
they are considered passive assets. 
  

	 	•	 	CFC/PFIC Overlap Rule: A foreign corporation is not a PFIC with respect to a particular U.S. investor if the foreign corporation is (i) a CFC and (ii) the U.S. investor is a U.S. Shareholder.

	 	•	 	PFIC Taint. Except as noted below, if a foreign corporation is a PFIC at any time when a U.S. shareholder hold stock of such corporation, the stock will continue to be PFIC in the hands of the U.S. shareholder
(the “PFIC Shareholder”) notwithstanding that the foreign corporation never meets the Income Test or Asset Test again. 

  

	 	•	 	Example. Assume QBDH is a CFC. As a result, its must use the adjusted tax basis of its assets to determine whether it meets the Asset Test. After a financing transaction, the cash and other passive assets QBDH
represent more than 50% of its assets because no value is assigned to its intellectual property and other intangible assets. QBDH will not be considered a PFIC with respect to Galen Partners V, L.P., because Galen Partners V, L.P. is a U.S.
Shareholder. However, QBDH will be a PFIC with respect to Thomas Bologna because Thomas is not a U.S. Shareholder. 

 Excess
Distribution Regime. A PFIC Shareholder is taxed under the “excess distribution” regime. An excess distribution is (i) the amount of a distribution received by a PFIC Shareholder from a PFIC during the taxable year over 125%
of the average distributions received in respect of such stock during the 3 preceding taxable years, and (ii) any gain recognized from the disposition of PFIC stock. If a PFIC Shareholder receives an excess distribution, the amount of the
distribution is spread ratably to each day in the PFIC Shareholder’s holding period. The tax thereon is calculated by multiplying the income spread to each year by the highest ordinary income tax rate in effect for such year. An interest charge
is added to the tax as if the tax were due and payable with the return filed for that year and the tax is being paid late. 
  

	 	•	 	Dispositions of PFIC Stock. With very limited exceptions, gain realized upon a sale or exchange of PFIC Stock, including those which normally quality for nonrecognition treatment, e.g. tax-free reorganizations,
is recognized and taxed under the excess distribution regime. 

 Qualified Electing Funds. A U.S. shareholder is not taxed under
the excess distribution regime, if the shareholder makes an election to treat a PFIC as a “qualified electing fund” or “QEF”. A shareholder of a QEF must include in gross income, its pro rata share of the QEF’s earnings and
profits. This inclusion is divided between ordinary earnings and long-term capital gain. An investor must include its pro rata share of the QEF’s earnings and profits in gross income only for those years in which the QEF meets the PFIC
Income Test or Asset Test. If neither test is met in a particular year, the investor has no income inclusion for that year. 
  

	 	•	 	Election. A QEF election can be made only if the foreign corporation agrees before the election is made that it will make the information available to the U.S. shareholder necessary to file the U.S.
shareholders federal income tax return. The election must generally be made on or before the due date, including extensions, of the tax return the U.S. shareholder files for the first year in which the foreign corporation meets the PFIC Income Test
or Asset Test. 

  

	 	•	 	 Benefit of Election. The PFIC Income Test is based on gross income, (i.e., gross receipts less cost of goods sold but before the
deduction of period expenses such as R&D, administrative and marketing expenses). In contrast, a U.S. shareholder who has made a QEF election must include an amount in income only if the company has earnings and profits, (i.e.,
gross income in excess of period expenses). Accordingly, a QEF election made with respect to an early stage technology company will seldom result in an income inclusion for a U.S. shareholder. While an early stage technology company may meet the
PFIC Income Test (because its only gross income consists of interest on funds in its bank account) or, the PFIC Asset Test (because it is a CFC and has significant cash on hand after a financing), it often fails to generate earnings and profits in
those 

	 	 
years. Accordingly, a QEF election is generally advisable for an early stage foreign technology company if the foreign company meets the Income Test or Asset Test in order to avoid taxation under
the excess distribution regime when the U.S. shareholder sells its shares of company stock. 

 Annual Determinations. It seems unlikely
that QBDH will meet the Income Test in light of the fact that it currently has sales. It may however meet the Asset Test if it becomes a CFC and is required to use the adjusted tax basis of its assets to make this determination. While it is less
likely that QBDH will be a PFIC if it is not a CFC, it may nevertheless satisfy one of the tests under certain circumstances. Accordingly, it should (i) agree to provide each U.S. shareholder with the information necessary to prepare its U.S.
federal income tax return should the U.S. shareholder make a QEF election (to enable the U.S. shareholder to make the election), and (ii) determine annually whether it is a PFIC and if so, the pro rata share of each U.S. shareholders ordinary
income and capital gain. The statement attached as Exhibit I should be provided to the U.S. shareholder each year before the due date of its U.S. federal income tax return (March 15th for Galen
Partners V, L.P). 

 Exhibit I 

PFIC ANNUAL INFORMATION STATEMENT 

Quotient Biodiagnostics Holdings Limited 

1. This Information Statement is for the taxable year of Quotient Biodiagnostics Holdings Limited (the “Company”)
beginning on [                    ] and ending on
[                    ] (the “Taxable Year”) and is issued to [U.S. shareholder’s name] (“Investor”).

 2. For the Taxable Year, the Company: 

     was a passive foreign investment company (“PFIC”). 

     was not a PFIC (Skip Sections 3 and 4). 

3. The Investor’s pro-rata share of the Company’s ordinary earnings and net capital gain (as determined under U.S. federal
income tax principles) for the Taxable Year follows: 
 Ordinary Earnings:
                             

Net Capital Gain :
                             

4. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to the Investor during
the Taxable Year was - 
 Cash: U.S. $         

Fair Market Value of Property; U.S. $         

5. The Company will permit the Investor, its direct or indirect owners to inspect and copy the Company’s permanent books of
account, records, and such other Company documents as are necessary to establish that the Company’s ordinary earnings and net capital gain are computed in accordance with U.S. income tax principles. 

Date: [                    ] 

 

			
	Company
		
	By:	 	  

		
	Title:	 	Chief Executive OfficerEX-10.11

 Exhibit 10.11 

MASTER SERVICES AGREEMENT 

This Master Services Agreement (“Agreement”), effective as of April 1, 2013 (“Effective Date”), is
between Future Diagnostics BV, a Dutch Company having its registered office at Nieuweweg 279, 6603 BN Wijchen, The Netherlands (“Future”), and QBD (QSIP) Limited, having its registered office at Elizabeth House, 9 Castle Street, St
Helier, Jersey JE4 2QP, Channel Islands, and its subsidiaries (“Client”). Client and Future may be referred to individually as a “Party,” and collectively as the “Parties.” 

RECITALS 
  

	 	A.	Future is in the business of developing diagnostic assays and performing contract manufacturing services for its clients. 

  

	 	B.	Client is in the business of developing and commercializing diagnostic products. 

  

	 	C.	Client wishes to engage Future to either develop diagnostic assays for Client commercialization, and/or to perform certain contract manufacturing services for Client, as further specified herein; and Future is willing
to perform such services, all under the terms and conditions of this Agreement. 

 1. Definitions. 

1.1. “Affiliate” means any entity that is controlled by, controls, or is under common control with, a Party hereto, for so
long as such control exists, where “control” for purposes of this definition only means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of an entity, whether through the
ownership of voting securities, by contract, or otherwise. 
 1.2. “Applicable Laws” means federal, state local, national
and supra-national laws, statutes, rules and regulations, including any rules, regulations, guidance, guidelines or requirements of regulatory authorities, national securities exchanges or securities listing organizations, that are in effect from
time to time during the term of this Agreement to the extent the same apply to a particular activity hereunder and have binding force on the relevant Party. 

1.3. “Client Technology” means all Technology Controlled by Client as of the Effective Date and/or during the term of this
Agreement, and all Improvements thereto. Client Technology includes Developed Technology. 
 1.4. “Control” or
“Controlled” means, with respect to Technology and all associated intellectual property and industrial right, the possession by a Party of the right to grant a license or sublicense to such Technology as provided herein without the
payment of additional consideration to, and without violating the terms of any agreement or arrangement with, any third party and without violating any Applicable Laws. 

1.5. “Developed Technology” means any Technology other than Future Technology that is developed, conceived or first reduced
to practice by Future specifically for Client and using Client Confidential Information in its performance of a Statement of work. Developed Technology includes Deliverables (defined in Section 2.5) and excludes Joint Technology. 

1.6. “Development Services” means contract assay development services performed by Future for Client pursuant to a Statement
of Work. 

 1.7. “Future Technology” means all Technology that is used by Future, or
provided by Future for use, in the performance of Services that is (a) Controlled by Future as of the Effective Date or (b) authored, invented, developed, conceived or first reduced to practice by Future after the Effective Date either
(x) other than in performance of the Services; and/or (y) without the use of any Materials or Client Confidential Information; and Improvements to the foregoing (a) and (b). Without limiting the foregoing, Future Technology includes
analytical methodology (including, without limitation, testing methods, practices, procedures or other methodological innovations, and reagents and materials related thereto, excluding Materials), methods and processes of manufacturing, and
modifications to Future’s facilities and equipment. 
 1.8. “Improvement” means any improvement, modification,
enhancement, derivative work, additive element or extension to any technology, invention, discovery or work of authorship. 
 1.9.
“Joint Technology” means any Technology that is invented jointly by Future and Client in their performance of a Statement of Work, and that does not use Client Confidential information. 

1.10. “Manufacturing Services” means contract manufacturing services performed by Future for Client pursuant to a Statement
of Work. 
 1.11. “Materials” means materials, equipment, instruments, reagents, biological materials, consumables, and any
other tangible items provided by Client to Future as described in the applicable Statement of Work, as well as all information concerning the stability, storage and safety requirements of such materials and other information related to such
materials as may be needed by Future to perform the Services. 
 1.12. “Product” means a product manufactured by Future for
Client in performance of Manufacturing Services. 
 1.13. “Purpose” means, with respect to any given Statement of Work,
Client’s use of the Deliverables solely for the purpose identified in such Statement of Work. 
 1.14. “Services”
means the services performed by Future for Client pursuant to a Statement of Work, including without limitation Manufacturing Services. 

1.15. “Specifications” means the requirements, standards, quality assurance and control parameters, and other specifications
provided by Client to Future for the Development Services or Manufacturing Services as detailed in a Statement of Work. 
 1.16.
“Technology” means all inventions, discoveries, Improvements, trade secrets and proprietary methods, and all technology, works of authorship, designs, processes, techniques, formulations, processes, know-how, computer programs,
databases, trade secrets, designs, marketing plans, product plans, design plans and business strategies, and in each case whether patentable or not, or susceptible to copyright, trade secret, or any other form of legal protection under Applicable
Law, and all right, title and interest in and to such items, including, without limitation, all copyrights, patent rights, trade secrets, trademarks, moral rights and all other applicable proprietary and intellectual property rights throughout the
world. 
 2. Services. 
 2.1.
Request for Services. Client may, from time to time, request Future to perform Services pursuant to the terms of this Agreement. When such requests are made, Client and Future will work together to develop a statement of work describing such
Services as described more fully in Section 2.2. 

  
 2 

 2.2. Statements of Work. Future will provide Client the Services as specified in a written
statement of work signed by both parties (“Statement of Work” or “SOW”). A form of SOW is attached hereto as Exhibit A. Each SOW should include, as applicable, the following details regarding the Services: scope,
deliverables, Specifications (whether for contract Development Services or Manufacturing Services), fees and compensation, timelines, and such other details as the Parties may agree. Upon execution by the Parties, each SOW will become part of this
Agreement and be subject thereto. If the terms of any SOW conflict with the terms of this Agreement, then the terms of this Agreement will govern unless specifically otherwise stated in the SOW, in which case the SOW term shall govern only with
respect to such SOW. If Client requests any changes to the Services, Future will inform Client of the cost and impact of such changes and will not implement any change without a fully executed amendment or change order to the relevant SOW. Prior to
commencement of Services under any SOW, Client shall either submit a written purchase order or include a purchase order in the SOW, and such purchase order or purchase order number will be valid for all invoicing under such SOW. 

2.3. Project Team. Each Party will identify a project leader (“Project Leader”) who will be such Party’s primary
point of contact under this Agreement to manage the SOW process. The Project Leaders will meet and confer to discuss, negotiate, draft and execute Statements of Work, and who will regularly meet and confer to discuss the progress of the SOW and
conduct all administrative efforts involved in performing the SOW. The Project Leader of each Party does not have the power or authority to represent such Party for purposes of amending this Agreement or any SOW. 

2.4. Materials. Client will provide certain Materials to Future in connection with the Services. Future shall use reasonable care in
safeguarding, inventorying and handling the Materials and will not use Materials for any purpose other than as permitted by the relevant SOW and this Agreement. Client will provide Future with information relevant to the safe and authorized use,
storage or handling of Materials, other than routine laboratory risks for materials of the same nature. Future acknowledges the Materials are made available for research use only and may not be used in humans. Future shall retain control of the
Materials and shall not distribute or release the Materials to any person or entity other than employees and agents of Future who are: (a) under Future’s direct supervision and control and (b) have a need to access the Material in
connection with the Services. Future will retain all Materials during the conduct of the Services and, upon Client’s written request and expense, will return unused Materials to Client. Absent such request, Future will dispose of such unused
Materials. For Materials that constitute equipment or instruments (“Equipment”), Client shall purchase, insure and retain ownership of the Equipment, and shall, as between the Parties, be the sole and exclusive owner of the
Equipment. Future shall use commercially reasonable efforts to maintain the Equipment in proper working condition. Client shall be responsible for the risk of loss of Materials except where such loss is caused by Future’s gross negligence or
willful misconduct. 
 2.5. Deliverables. For assay development Services, Future will provide the direct results of its performance
of the Services to Client, including but not limited to data, assays, reports and other deliverables as set forth in each SOW (“Deliverables”), and shall use commercially reasonable efforts to develop and deliver the Deliverables in
accordance with the timetable established in such SOW. Future will notify Client if Future determines that there are likely to be substantial delays. Client acknowledges that, due to the nature of the Services, Future cannot guarantee that any
Deliverable will be developed or delivered. Future shall keep Client reasonably informed of Future’s progress in developing and delivering Deliverables, provide Client a reasonable opportunity to review and comment on interim draft reports, and
take account of any such comments with respect to such Deliverables. Client’s use (including without limitation copying, modification and distribution) of Deliverables is subject at all times to the restrictions in Section 6.4.5. 

2.6. Client Obligations. Client acknowledges that its timely provision of, and Future’s access to, all relevant Client assistance,
cooperation, and complete and accurate information and data and Materials is essential to the performance of the Services, and that Future shall not be liable for any deficiency or delay in performing the Services if such deficiency or delay results
from Client’s failure to provide full cooperation as required in this Section. 

  
 3 

 
Client shall provide Future with all information available to Client regarding known or potential hazards associated with the use of any materials or substances supplied to Future by Client. 

2.7. Non-exclusivity. Client acknowledges that all Services are provided on a non-exclusive basis, and Future reserves all rights for
itself and its Affiliates to provide third parties with deliverables that are identical or similar to Deliverables, including results or work product generated using materials that are similar or identical to Materials, provided however that Future
shall not use any Client Confidential Information, Developed Technology or Materials to perform Services for any third party. 
 3. Conduct of
Services. 
 3.1. General. Future will conduct the Services: (a) in a diligent and professional manner, (b) with
reasonable due care and in conformity with current generally accepted standards and procedures for such type of services; and (c) in compliance with Applicable Laws; provided, however, that Future is not obligated to perform the Services in
compliance with Applicable Laws where such conduct is pursuant to Client’s written instructions or Specifications and/or in reliance upon or use of Materials in accordance with this Agreement. For contract manufacturing Services, Future will
use commercially reasonable efforts to manufacture the Product in accordance with the Specifications and the relevant SOW. Future will use commercially reasonable efforts to perform Services and deliver Deliverables pursuant to each SOW. 

3.2. Quality Assurance. Future shall, in performing Services, maintain internal quality processes, including without limitation design
control, that are (i) International Standards Organization (ISO) 13485 registered; and (ii) in compliance with the In Vitro Diagnostics Directive (IVDD) and the FDA’s Quality System Regulation (QSR) for medical devices or
substantially similar registration or regulation. Upon request, Future shall provide Client a copy of Future’s internal guidelines for testing, quality control, documentation, record-keeping and standard and general operating procedures used in
connection with the Services, and shall share with Client the results of any inspection by a government agency that may affect the Services. 

3.3. Inspections. Upon at least thirty (30) days prior written notice and during Future’s regular business hours, Future will
allow Client authorized representatives, at any time during the term of an applicable SOW to: (a) inspect that portion of Future’s facility used in the performance of the Services; (b) monitor the conduct of such Services; and
(c) communicate with Future personnel performing the Services. Such examination may be conducted so long as it does not unreasonably interfere with Future’s operations. Future shall not be obligated to provide Client representatives with
access to information or facilities not directly related to the Services, and Future may require that Client’s representatives conducting any such examination or inspection first execute Future’s form of non-disclosure agreement. 

3.4. Records. Future will collect and prepare records and reports generated in performance of the Services, and will maintain such
records and reports during the term of this Agreement. Designated representatives of Client shall, upon reasonable notice to Future, have access to and shall be permitted to review such records. Upon termination of this agreement, or earlier, if
requested by Client, Future will, as instructed by Client, either (a) return the Records in such form as is then currently in the possession of Future, or (b) destroy the Records; provided, however, that Future may retain copies of any
Records as are reasonably necessary for regulatory or insurance purposes or for compliance with Applicable Laws, subject to Future’s obligations of confidentiality. Notwithstanding the foregoing, to the extent that Future’s lab notebooks
contain Deliverables or Client Confidential Information, such Deliverables and Confidential Information will continue to be the property of the Client, and such portions of such notebooks and records will be subject to Future’s obligations of
nonuse and confidentiality as set forth in Section 5. 
 3.5. Research Management Committee. As soon as practicable upon the
effective date of any given Statement of Work, the Parties shall establish a research management committee (“RMC”) comprised of up to four 

  
 4 

 
(4) members, with an equal number of representatives designated by each Party. The RMC shall: (i) coordinate cooperation between the Parties with respect to the SOW, (ii) monitor
performance of the SOW, (iii) attempt to resolve disputes between the Parties with respect to performance of the SOW; and (iv) perform such functions as appropriate to further the purposes of this Agreement and as the Parties may designate
from time to time. The RMC shall meet in person or by teleconference on a quarterly basis, or more or less frequently as its members may mutually agree. If the RMC is unable within thirty (30) days of resolving a decision or dispute as to any
matter, an executive officer of each Party shall meet and seek diligently and in good faith to resolve the deadlock. For the avoidance of doubt, RMC decisions do not qualify as binding third-party rulings and the RMC may not enter into or agree upon
any decision binding the Parties, but acts only as a mediator for the Parties’ convenience. 
 4. Payment. 

4.1. Terms. Client will compensate Future for its performance of the Services in accordance with the terms set forth in each SOW.
Client will also reimburse Future for reasonable, necessary and documented expenses directly incurred in connection with the Services. 

4.2. Invoices. Except for revenue sharing or earn-out fees payable by Client to Future (if at all) under a SOW, Future will invoice
Client for fees and costs payable under each SOW and send such invoices to the attention of Client’s Accounts Payable Department or such other department or person as specified in the relevant SOW. All invoices will contain an itemization of
fees and expenses. Client shall pay invoices conforming to this Section within thirty (30) days from receipt. All payments shall be made in Euros by wire transfer in immediately available funds to a bank and account designated in writing by
Future or by check made payable to Future, unless otherwise specified in the SOW or invoice. All payment obligations are stated and shall be paid net of any taxes. Client may not set off or deduct any amounts from fees owed to Future hereunder
without Future’s prior written consent. 
 4.3. Late Payment. If any payment due hereunder is not made when due, then, without
limiting Future’s other available remedies, (a) Future may suspend performance of Services until all past due amounts are received and/or (b) the underpayment shall accrue interest from the date due at the maximum legal annual
commercial interest rate per month per article 6:119a of the Netherlands Civil Code. 
 5. Confidentiality. 

5.1. “Confidential Information” means all business and proprietary information relating to each Party’s and its
Affiliates’ scientific, technical, business, financial or personnel information that is obtained by or given to the other Party hereunder, whether or not labeled or identified as “Confidential,” including, without limitation,
Materials (for Client), Future Technology (for Future), Deliverables and Joint Technology. 
 5.2. Exceptions. Confidential
Information does not include information that (a) the receiving Party previously knew about or obtained outside of any contractual relationship with the disclosing Party, as evidenced by the receiving Party’s regularly maintained records;
(b) is generally available to the public or publicly divulged through no fault of the disclosing Party, (c) is subsequently disclosed to the receiving Party by a third party, as evidenced by the receiving Party’s regularly maintained
records, where such third party is not under any obligation of confidentiality to the disclosing Party, and (d) information independently developed by the receiving Party without access to or use of the disclosing Party’s Confidential
Information, as evidenced by the receiving Party’s regularly maintained records. 
 5.3. Permitted Disclosures and Uses. Each
Party may use the other Party’s Confidential Information solely in furtherance of the performance of this Agreement and for no other purpose. Each Party will use the same degree of care to protect the other Party’s Confidential Information
as it uses to protect its own confidential information of like nature, but in no circumstances with less than reasonable care. Each Party agrees not to disclose 

  
 5 

 
the other Party’s Confidential Information to any person or entity other than: (a) employees, agents, subcontractors or consultants of the receiving Party on an as-needed basis,
provided such persons have entered into written confidentiality agreements consistent with this Section 5 or otherwise are bound under substantially similar confidentiality restrictions; (b) to the extent required by court order, legal
process or Applicable Law, provided that the receiving Party provides prompt advance written notice thereof (to the extent permitted by Applicable Law) to the disclosing Party; or (c) otherwise solely as expressly authorized in writing by the
disclosing Party. 
 5.4. Return of Confidential Information. Upon the disclosing Party’s request or upon any earlier
termination of this Agreement, the receiving Party will return or destroy the disclosing Party’s Confidential Information in its possession, as instructed by the disclosing Party. 

5.5. Residual Knowledge. Nothing contained in this Agreement, except as set forth in this Section 5, shall restrict Future from
the use of any general ideas, concepts, know-how, methodologies, processes, technologies, algorithms, or techniques of a general nature retained in the unaided mental impressions of its personnel which it develops or learns under this Agreement,
provided that in doing so Future does not breach its obligations under this Section 5. 
 5.6. Equitable Relief. Each Party
acknowledges that, during the course of performing Services hereunder, it will receive and gain access to Confidential Information relating to the other Party’s business, which is extremely competitive, and that such Party’s unauthorized
disclosure of any such Confidential Information would result in serious harm to the other Party. Each Party acknowledges and agrees that the restrictions set forth in Section 5 are reasonable and necessary to protect the legitimate interests of
the other Party, and, in the event of a breach or threatened breach of any provision of Section 5, the other Party will be authorized and entitled to request from any court of competent jurisdiction equitable relief, whether preliminary or
permanent, and specific performance, without posting a bond or other security and without proving damages. 
 6. Intellectual Property; Client
Restrictions. 
 6.1. Retained Rights. Each Party will retain all right, title and interest in all Technology that is Controlled
by it prior to the Effective Date and no license grant or assignment is implied (by estoppel or otherwise) with regard thereto. As between the Parties, Materials and Products are the sole and exclusive property of Client. Notwithstanding anything to
the contrary herein, Client shall not by virtue of this Agreement or either Party’s performance thereof obtain any intellectual property or other ownership rights in any methods or processes used or developed by or for Future in or for the
provision of Services, or any documentation (other than Specifications), records, raw data, materials (other than Materials), specimens, work product, concepts, information, inventions, Improvements, designs, programs, formulas, know-how, or
writings related thereto. 
 6.2. License Grants. 

6.2.1. By Client. Client hereby grants to Future a worldwide, limited, non-transferable (except in connection with an assignment as
permitted in Section 13.6), non-sublicensable, nonexclusive royalty-free, fully paid up license to use Client Technology, Client’s interest in Joint Technology, Specifications and Materials solely to perform the Services in accordance with
the relevant SOW. 
 6.2.2. By Future. Subject to Client’s fulfillment of its payment obligations pursuant to the relevant SOW
and compliance with this Agreement, and unless specifically stated otherwise in a relevant Statement of Work, Future hereby grants to Client a worldwide, limited, non-transferable (except in connection with an assignment as permitted in
Section 13.6), non-sublicensable, nonexclusive, royalty-free, fully paid up license under Future’s right, title and interest in and to Future Technology to use Future Technology solely to the extent reasonably necessary to practice and
commercialize the Developed Technology in furtherance of the Purpose. 

  
 6 

 6.3. Developed Technology. As between the Parties, and subject to Client’s
fulfillment of its payment obligations pursuant to the relevant SOW (which payment may include earn-out or other fees) and compliance with this Agreement (including without limitation Section 6.4.5), Client will solely and exclusively own all
right, title and interest in and to any and all Developed Technology. Future hereby assigns to Client all right, title and interest in and to any and all Developed Technology, whether existing now or at any time in the future by way of assignment of
future copyright or other intellectual property rights. 
 6.4. Joint Technology. 

6.4.1. Each Party shall have a complete and undivided ownership interest in all Joint Technology, and shall have the right, subject to the
provisions of this Agreement, to practice and to grant licenses under Joint Technology without the consent of, or compensation or accounting to, the other Party, subject at all times to the restrictions in Section 6.4.5. 

6.4.2. Client hereby grants to Future a worldwide, nonexclusive, sublicensable, royalty-free, fully paid up license under Client’s
right, title and interest in and to Joint Technology to use and practice the Joint Technology without restriction. Unless specifically stated otherwise in a relevant Statement of Work, Future hereby grants to Client a worldwide, limited,
non-transferable (except in connection with an assignment as permitted in Section 13.6), non-sublicensable, nonexclusive, royalty-free, fully paid up license under Future’s right, title and interest in and to Joint Technology to use Joint
Technology solely to the extent reasonably necessary to practice and commercialize the Developed Technology in furtherance of the Purpose, or for any other Client purpose, as mutually agreed-upon by both Parties. 

6.4.3. The Parties shall together determine whether, to what extent, and how to file, prosecute or maintain any patent or patent application
that claims any Joint Technology, or whether to maintain as a trade secret any Joint Technology, and the allocation of costs and fees with respect to any such protection. Unless agreed to otherwise by the Parties in writing, all costs and expenses
incurred in the drafting, filing, prosecution and maintenance of any Joint Patent shall be shared equally by the Parties. Should a Party wish not to bear its share of the cost of filing, prosecuting or maintaining any Joint Patent, it shall notify
the other Party in writing, and the Parties shall discuss whether to maintain the subject Joint Technology as a trade secret, allow the other Party to bear all costs of filing, prosecuting and/or maintaining such Joint Patent, or other arrangement.

 6.4.4. Subject to contractual obligations of confidentiality, if any, each Party will promptly notify the other in writing of any
alleged or threatened misappropriation or infringement by any third party, direct or indirect, of any Joint Technology of which it becomes aware, and shall provide the other Party with all available evidence, if any, of such infringement or
misappropriation, and the Parties shall together determine the method, manner and allocation of costs in taking appropriate action against any such third party. 

6.4. 5. Neither Party shall enter into any settlement, consent judgment, or other voluntary final disposition of any infringement action with
respect to Joint Technology without the prior written consent of the other Party, which consent shall not be unreasonably withheld or denied. 
  

	 	6.5.	 Restrictions on Use. Notwithstanding anything to the contrary herein, Client may use Joint Technology solely for the Purpose, or for any other
Client purpose, as mutually agreed-upon by both Parties, and may not make, use, sell, have sold, offer for sale, transfer, lease, or otherwise distribute any product or service that is covered by or practices or embodies Joint Technology (or any
portion thereof or any derivative thereof or any Improvement thereof) in any other manner or for any other purpose. Client may not assign, sell, transfer, lease, license or otherwise convey or encumber any of its rights, title or interest in and to
Joint Technology to any third party or Affiliate without Future’s prior express written consent, except in 

  
 7 

	 	
connection with an assignment as permitted in Section 13.6. Client agrees its breach of this Section will result in irreparable and continuing damage to Future for which there will be no
adequate remedy at law; therefore, in the event of a breach or threatened breach of any provision of this Section, and without limiting its other available remedies, Future shall be entitled to equitable relief, whether preliminary or permanent, and
specific performance, without posting a bond or other security and without proving damages, and Client shall not oppose the granting of such relief. 

6.6. Assistance. Future will, and will cause its employees and representatives to, execute all documents and perform all reasonable and
necessary acts to evidence ownership by Client of the Developed Technology and Deliverables, at Client’s expense. 
 7. Warranties and
Disclaimer. 
 7.1. Express Warranty. Future warrants to Client that Future shall perform the Services in accordance with the
standards of Section 3.1 and Section 3.2. Any Services provided by Future that do not conform to the foregoing express warranty will be corrected by Future without charge to Client, or Future will refund to Client amounts paid in respect
of such nonconforming Services, in each case provided that Client provides written notice of the nonconformity within (90) days after completion of the relevant portion of the Services. The parties acknowledge and agree that Future does not
warrant or represent that Products Developed Technology or any other results of the Services will be acceptable to any regulatory governmental agency to which they are presented nor that the Products, Developed Technology, or any other results of
the Services will enable Client to market or otherwise exploit any given product or service. The foregoing re-performance or refund constitute Client’s sole and exclusive remedy for a breach of warranty. 

7.2. Client Warranties. Client represents and warrants to Future that Client has the right to provide the Specifications and the
Materials to Future as contemplated by this Agreement. 
 7.3. Disclaimer. Except as expressly set forth in Section 7.1 and
Section 7.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS OR WARRANTIES OF ANY KIND WITH RESPECT TO THIS AGREEMENT OR ITS SUBJECT MATTER, EITHER EXPRESS OR IMPLIED, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT,
MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE. CLIENT ACKNOWLEDGES THAT ALL PRODUCTS AND DELIVERABLES ARE MADE AVAILABLE BY FUTURE “AS IS” AND WITHOUT WARRANTY, AND FUTURE MAKES NO WARRANTY OR REPRESENTATION THAT ANYTHING MADE,
USED, SOLD OR OTHERWISE DISPOSED OF UNDER ANY LICENSE GRANTED OR ASSIGNMENT MADE IN THIS AGREEMENT IS OR WILL BE FREE FROM INFRINGEMENT OF ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHT OF ANY THIRD PARTY. 

8. Indemnification. 
 8.1. Future
Indemnification. Future will indemnify, defend and hold harmless Client and its Affiliates from and against any and all damages, liabilities, losses, costs and expenses (including, but not limited to, reasonable attorneys’ fees)
(collectively, “Losses”) resulting from any third-party claim, suit, action, investigation or proceeding (each, an “Action”) brought against Client or its Affiliates to the extent such Losses are caused by Future
(a) breach of the express warranty made by Future in Section 7.1 except where such breach is a result of Future’s reliance upon Specifications or Client’s written instructions; and/or (b) gross negligence or willful
misconduct. 
 8.2. Client Indemnification. Client will indemnify, defend and hold harmless Future and its Affiliates from and
against any and all Losses relating from any Action brought against Future or its Affiliates to the extent such Losses are caused by or are related to (a) the Materials and/or the Specifications, including without limitation Future’s use
thereof or reliance thereon in accordance with the respective SOW; (b) any product or service based in 

  
 8 

 
whole or in part on the Specifications; (c) Client’s reliance on or use of Developed Technology or any portion thereof, or any derivative thereof (including without limitation the
manufacture, use, sale and/or import of Developed Products, if any as defined in the relevant SOW; (d) Client’s breach of the express warranty made by Client in Section 7.2; and/or (e) Client’s gross negligence or willful
misconduct. 
 8.3. Indemnification Conditions. Indemnification under Section 8.1 and Section 8.2 will be provided on the
condition that: (i) the indemnified Party gives written notice to the indemnifying Party as soon as possible upon the indemnified Party becoming aware of the subject Action (provided failure to give such notice within such period will not bar a
claim for indemnification except to the extent such failure has materially prejudiced the indemnifying Party); (ii) the indemnifying Party has sole control of the defense and all related settlement negotiations, provided any settlement that
would impose any admission of liability by the indemnified Party will be subject to such Party’s prior written approval, not to be unreasonably withheld; and (iii) the indemnified Party provides cooperation and information in furtherance
of such defense, as reasonably required by the indemnifying Party, at the indemnifying Party’s expense. 
 9. Limitation of Liability. To the
maximum amount permitted under Applicable Laws, and except for (i) amounts owed by the indemnifying Party to a third party pursuant to the indemnifying Party’s indemnification obligations under Section 8, or (ii) claims arising under
Section 5 and/or Section 6.4.5: (a) in no event will either Party be liable to the other for special, indirect, incidental, punitive, exemplary or consequential damages (including, but not limited to, loss of profits, cost of cover,
loss of data or loss of use damages) even if such Party has been advised of the possibility of such damages or losses, and regardless of legal theory (whether based on breach of contract, breach of warranty, negligence or any other legal theory);
and (b) except for amounts owed by Client hereunder, the entire liability of each Party to the other in connection with this Agreement will not exceed, in the aggregate, the total amount of fees paid by Client to Future under the Statement(s)
of Work under which the liability arose. This Section is without prejudice to Section 7.1, with respect to which Future’s entire liability is limited to re-performance or refund as specified therein. 

10. Insurance. Each Party shall, at its sole expense, obtain and maintain appropriate public liability and casualty insurance with insurance companies
having an A. M. Best Rating of “A-, VII” or better, or adequate levels of self insurance, to insure against any liability caused by such Party’s performance under this Agreement. Each Party shall furnish the other Party with
certificates of insurance showing compliance with all requirements set forth in this Section upon receipt of written request. 
 11. Term and
Termination. 
 11.1. Duration. This Agreement will commence on the Effective Date and continue in effect until terminated in
accordance with this Section 11 or by delivery of written notice of termination by either Party to the other after completion of performance or termination of all SOWs in accordance with their terms. 

11.2. Mutual Termination Rights. Each Party may terminate this Agreement, or any SOW, immediately upon written notice if the other
Party: (i) becomes insolvent; (ii) becomes the subject of a petition in bankruptcy which is not withdrawn or dismissed within 120 days thereafter; (iii) makes an assignment for the benefit of creditors; or (iv) breaches any
material obligation under this Agreement (including but not limited to payment obligations) and fails to cure such breach within thirty (30) days after delivery of notice thereof by the non-breaching Party. 

11.3. Client Termination Right. Client may terminate this Agreement or any SOW for any reason upon ninety (90) days written notice
to Future. 

  
 9 

 11.4. Future Termination Right. If Future, in its reasonable discretion, applying
analytical methods reasonably selected by it and accompanied by documentation, determines that continuing performance of the Services in accordance with the SOW is not likely to result in delivery of any given Deliverable or achievement of any given
milestone, then Future shall so notify Client, and Future’s obligation to perform Services under such SOW shall be suspended. Client shall notify Future within five (5) business days whether or not Client agrees with Future’s
position. If Client does not agree, then the Parties shall submit the dispute to the Resolution Management Conference (RMC) for resolution. If the RMC does not resolve the dispute within ten (10) business days, then Future may terminate the
relevant SOW upon notice to Client. If Future terminates a SOW pursuant to this Section and if the SOW included milestone payments, the Parties shall cooperate in good faith to allocate fees payable to Future in respect of the next-occurring
milestone, which fees shall be reasonable and prorated, taking into account the work actually performed by Future in efforts to achieve the next-occurring milestone, and Client shall pay such fees in response to Future’s invoice therefor. 

11.5. Payments Due Upon Termination. Upon termination of this Agreement or any SOW, Client will pay Future all fees and expenses due
and incurred through the effective date of termination. If the termination was effected by Client under Section 11.3 or by Future under Section 11.2, then (a) Client shall reimburse Future for all non-cancellable commitments incurred
by Future in connection with the performance of the Services prior to the effective date of such termination; and (b) if the terminated SOW included milestone payments, then Client will pay Future the amount due for the next-occurring
milestone. 
 11.6. SOW Terminations. The provisions of this Agreement will remain unaffected by any termination of an individual
SOW. Termination of this Agreement shall immediately and automatically terminate all outstanding SOWs. 
 11.7. Survival.
Notwithstanding anything else in this Agreement, the provisions of Section 2.7, all payments, if any, payable by Client to Future under a Statement of Work, and Sections 4 through 13 (inclusive) of this Agreement will survive termination or
expiration of this Agreement for any reason. 
 12. Governing Law. This Agreement will be governed by the laws of the Netherlands, except that
matters pertaining to patents and other intellectual property rights shall be governed by the laws of the jurisdiction in which such intellectual property rights exist. The Agreement shall not be governed by the United Nations Convention on
Contracts for the International Sale of Goods nor by the Vienna Sales Convention, nor by title 7:1 of the Netherlands Civil Code. All disputes arising out of this Agreement are subject to the exclusive jurisdiction of the courts located in
Amsterdam, The Netherlands, and the parties hereby submit to the personal jurisdiction and venue of these courts; provided, however, that either party may seek injunctive relief and the enforcement of judgments in any court of competent
jurisdiction, no matter where located. The prevailing party in any action or proceeding brought at law or equity (where for purposes of this sentence the granting of equitable relief shall be considered “prevailing”) shall be entitled to
recover from the other party such party’s costs and expenses, including without limitation reasonable attorneys’ fees incurred in relation to such action or proceeding. 

13. Miscellaneous. 
 13.1. Independent
Contractors. The Parties are independent contractors, and nothing contained in this Agreement will be construed to place the Parties in the relationship of employer and employee, partners, principal and agent or joint venturers. Neither Party
will have the power to bind or obligate the other Party, nor will either Party hold itself out as having such authority. 
 13.2.
Publicity. The Parties agree that each shall obtain the other’s prior written approval before using the other’s name, logos and/or marks in any form of publicity. Such obligation shall not apply to disclosures which

  
 10 

 
either Party is required by Applicable Law to make, provided that the disclosing Party shall notify the other Party of any such disclosure prior to such disclosure. 

13.3. Waivers. To the extent consistent with the laws of the Netherlands, the failure of either Party to take action as a result of a
breach of this Agreement by the other Party will constitute neither a waiver of the particular breach involved nor a waiver of either Party’s right to enforce any provision of this Agreement through any remedy granted by law or this Agreement.
All rights and remedies, whether conferred hereunder, or by any other instrument or law, unless otherwise expressly stated, will be cumulative and may be exercised singularly or concurrently. 

13.4. Severability. If any of this Agreement is found to be invalid or unenforceable by a court of competent jurisdiction, such
provision shall be severed and deleted, and such finding will not invalidate any other terms of this Agreement, and those terms will remain in full force and effect. 

13.5. Integration and Amendments. This Agreement, including each SOW, contains the entire understanding of the Parties with respect to
the subject matter hereof, and supersedes all prior and contemporaneous written or oral communications. This Agreement and each SOW may not be modified or amended except by an instrument in writing signed by both Parties. No pre-printed terms of any
subsequent purchase order or invoice will add to, modify, or supersede the terms of this Agreement. 
 13.6. Assignment. Except as
expressly provided below, the rights and license granted by Future to Client in this Agreement are personal to Client (and do not, for example, extend to any Affiliate of Client or any other entity), except as expressly permitted in this Section.
Neither Party may assign this Agreement or any part hereof without the prior written consent of the other Party; provided, however, that each Party may, upon notice to the other Party, assign this Agreement in its entirety without the
other Party’s consent in connection with the transfer or sale of all or substantially all of such Party’s business or assets to which this Agreement relates to a third party, whether by merger, sale of stock, sale of assets or otherwise,
including pursuant to a Change of Control. “Change of Control” means, with respect to a Party, (a) a merger, consolidation, share exchange or other similar transaction involving such Party and any Third Party which results in
the holders of the outstanding voting securities of such Party immediately prior to such merger, consolidation, share exchange or other similar transaction ceasing to hold more than fifty percent (50%) of the combined voting power of the
surviving, purchasing or continuing entity immediately after such merger, consolidation, share exchange or other similar transaction, (b) any transaction or series of related transactions (other than an investment transaction by an entity not
engaged in the pharmaceutical or biotechnology business, the purpose of which is to raise capital for a Party) in which a third party, together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined
voting power of the outstanding securities or such Party, or (c) the sale or other transfer to a third party of all or substantially all of such Party’s assets which relate to this Agreement. This Agreement binds and benefits the Parties
and their respective permitted successors and assigns. 
 13.7. No Third-Party Beneficiaries. This Agreement is intended to be solely
for the benefit of the Parties hereto and is not intended to confer any benefits upon, or create any rights in favor of, any other person. 

13.8. Notices. A notice or consent that occurs will become effective when the intended recipient receives it. All such notices and
consents must be in writing and delivered personally, by facsimile transmission with answer back confirmation or by overnight commercial courier, to the Parties at the following addresses or facsimile numbers: 

 

					
	If to Client:	  	 	  	If to Future:
	QBD (QSIP) Limited	  	Future Diagnostics BV	  	
	Suite S-204	  		  	Nieuweweg 279, 6603 BN Wijchen

  
 11 

					
	301 South State Street	  		  	The Netherlands
	Newtown, Pa, 18940, USA	  		  	Attention: MIKE MARTENS
	Attention: Jeremy Stackawitz	  		  	Facsimile: +3124 6452899

 13.9. Force Majeure. Except with respect to payment obligations, and to the extent consistent with the
laws of the Netherlands, if either Party is delayed or prevented from fulfilling its respective obligations under this Agreement by any cause beyond its reasonable control, then such performance shall be excused to the extent of the delay or
failure, and that Party will not be liable under this Agreement for that delay or failure. 
 13.10. Counterparts. This Agreement may
be executed in counterparts all of which taken together will constitute one agreement. 
 [THE REMAINDER
OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.] 

  
 12 

 To evidence the Parties’ agreement to this Agreement, they have signed and delivered it effective as of
the Effective Date. 
  

									
	[Client]	 		 	Future Diagnostics BV
				
		 	QBD (QSIP) Limited	 		 	
					
		 	 /s/ Jeremy Stackawitz
	 		 		 	 /s/ Mike Martens

		 	  
	 		 		 	  

					
	Name:	 	 Jeremy Stackawitz
	 		 	Name:	 	 MIKE MARTENS

					
	Title:	 	 President
	 		 	Title:	 	 MANAGING DIRECTOR

					
	Date:	 	 April 1, 2013
	 		 	Date:	 	 April 2, 2013

  

  
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]